The matrix metalloproteinases (MMPs) comprise a family of at least 20 proteolytic enzymes that play an essential role in tissue remodeling. MMP1 (interstitial collagenase), MMP9 (gelatinase B) and MMP12 (macrophage elastase) are thought to be important in the development of emphysema. A number of naturally occurring polymorphisms of human MMP gene promoters have been identified and found to alter transcriptional activity. Additionally, we detected a novel polymorphism in the MMP12 coding region (Asn357Ser). The aim of this study was to investigate the role of MMP polymorphisms in the development of chronic obstructive lung disease. We determined the prevalence of these polymorphisms in 590 continuing smokers chosen from the National Heart Lung and Blood Institute, Lung Health Study for having the fastest (n = 284) and slowest (n = 306) 5 year rate of decline of lung function. Of the five polymorphisms, only G-1607GG was associated with a rate of decline in lung function. The -1607GG allele was negatively associated with a fast rate of decline (P = 0.02). However, haplotypes consisting of alleles from the MMP1 G-1607GG and MMP12 Asn357Ser polymorphisms were associated with rate of decline of lung function (P = 0.0007). These data suggest that polymorphisms in the MMP1 and MMP12 genes, but not MMP9, are either causative factors in smoking-related lung injury or are in linkage disequilibrium with causative polymorphisms.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is characterized by decreased expiratory flow rates, increased pulmonary resistance and hyperinflation of the lung. Cigarette smoking is the most important risk factor for the development of COPD but only a minority of smokers develop symptoms (1) . Smoking leads to two pathophysiologic processes in the lung. The first is proteolytic destruction of the lung parenchyma, which results in permanent enlargement of airspaces (emphysema) and, consequently, loss of lung elastic recoil. The second is inflammatory narrowing of peripheral airways, which is characterized by edema, mucus hypersecretion and fibrosis of peripheral airways. Evidence of both pathophysiologic processes is usually found in an individual COPD patient.
A proteinase-antiproteinase imbalance has been the most widely accepted theory for the pathogenesis of pulmonary emphysema since the discovery of α-1-antitrypsin deficiency (2) . Matrix metalloproteinases (MMPs) comprise a structurally and functionally related family of at least 20 proteolytic enzymes, which play an essential role in tissue remodeling and repair associated with development and inflammation (3) . MMP genes have been mapped to chromosomes 11, 14, 16, 20 and 22 , with several of them being clustered within the long arm of chromosome 11 (4) . Overexpression of metalloproteinases has been associated with several pathological conditions, including the irreversible degradation of tissues in arthritis (5) and the degradation of collagens in tumor invasion and metastasis leading to poorer prognosis in patients with higher expression of MMPs (6, 7) . Several studies in animals and humans have provided evidence that MMP1 (interstitial collagenase), MMP12 (human macrophage elastase) and MMP9 (gelatinase B) are important in airway inflammation and the development of emphysema. In 1992, D'Armiento et al. (8) demonstrated that transgenic mice over-expressing human MMP1 in their lungs developed morphologic changes strikingly similar to human pulmonary emphysema. MMP12 knockout mice did not develop emphysema following exposure to cigarette smoke compared to wild-type mice (9) , suggesting that the presence of MMP12 is critical in smoke-induced lung injury. Smokers with airway obstruction show increased expression of MMP1 and MMP9 compared to smokers without COPD and non-smokers (10, 11) .
Lung function normally increases to a maximal value at adulthood and begins to decline 10-15 years later (12) . COPD can develop because of a reduced maximal lung function, an earlier age of onset of decline or an accelerated rate of decline. The latter is thought to be related to genetic susceptibility to *To whom correspondence should be addressed. Tel: +1 604 806 9008; Fax: +1 604 806 8351; Email: asandford@mrl.ubc.ca cigarette smoke (1) . Family (13) and twin (14) studies have provided evidence that there is a genetic susceptibility for the development of COPD. There are a number of function-altering polymorphisms within the promoters of MMP genes (15) (16) (17) . Furthermore, we describe a novel polymorphism in the coding region of the MMP12 gene.
The aim of this study was to investigate the association of MMP polymorphisms with rate of decline of lung function in smokers. We selected 590 study subjects who had either a rapid decline or no decline in lung function over a period of 5 years. We hypothesized that polymorphisms that lead to increased expression of MMP genes or increased activity of the enzymes would be associated with a rapid rate of decline in lung function.
RESULTS
The characteristics of the 590 smokers are given in Table 1 . There were significant differences in several potentially confounding variables between the rapid and non-decliner groups. Therefore, the frequencies of the genotypes between groups were analyzed by binary logistic regression to adjust for these variables. Allele frequencies in our Caucasian study population (Table 2 ) were similar to those described previously (6, (16) (17) (18) . The overall observed distribution of homozygotes and heterozygotes for each polymorphism conformed to expectations based on Hardy-Weinberg analysis.
The frequency distribution of the MMP9 (CA-repeat) polymorphism showed a bimodal distribution of alleles (Table 2) . Therefore, for further analyses we divided the alleles into two subclasses according to the numbers of CA repeats. Alleles with (CA) ≤16 were designated as 'small' and alleles with CA repeats (CA) ≥17 were designated as 'large'. The -1607GG allele was negatively associated with a fast rate of decline [odds ratio (OR) = 0.76, 95% confidence interval (95% CI) 0.60-0.96, P = 0.02].
There was no association with rate of decline of lung function with any genotype (Table 3 ). However, there was a trend for an association (P = 0.05) between MMP1 (G-1607GG) containing genotypes and rate of decline of lung function.
Possession of either one or two copies of the -1607GG allele was negatively associated with a fast rate of decline (OR = 0.62, 95% CI 0.42-0.92, P = 0.02). This association remained significant after adjustment for smoking history, age, sex and initial level of lung function (adjusted OR = 0.62, 95% CI 0.41-0.94, P = 0.02).
There was strong linkage disequilibrium (LD) between the C allele of MMP9 (C-1562T) and small variants of the MMP9 (CA-repeat) (D/Dmax = 0.96, P < 0.00001). There was also strong LD between the MMP1 (G-1607GG) and MMP12 (A-82G) alleles (D/Dmax = 0.76, P < 0.0001). The MMP1 and MMP12 genes are both located on chromosome 11q22-q23 (4). In contrast, the two MMP12 polymorphisms were not in LD.
Haplotype analysis of the two MMP12 and the two MMP9 polymorphisms did not reveal an association with rate of decline of lung function (data not shown). Similarly, MMP1 (G-1607GG)/MMP12 (A-82G) haplotypes were not associated with rate of decline of lung function. However, there was an association of MMP1 (G-1607GG) and MMP12 (Asn357Ser) haplotypes with rate of decline of lung function (Table 4) . If these data are adjusted for multiple comparisons (five allele frequency comparisons, five genotype frequency comparisons and four haplotype frequency comparisons) by the Bonferroni approach, this association remains significant (P = 0.0007 × 14 = 0.0098). However, this correction is probably over-conservative given that the alleles, genotypes and haplotypes at each locus and in some cases between loci are not independent of each other.
DISCUSSION
In this study, we investigated the role of common polymorphisms within several MMP gene promoters in smoking-induced lung injury. We were able to exclude a major contribution of these polymorphisms individually on rate of decline in lung function of smokers. We describe a novel polymorphism in MMP12, and a novel assay for rapid genotyping of MMP1. Furthermore, we demonstrated that MMP1/MMP12 haplotypes were associated with rate of decline of lung function.
MMPs are interesting candidate genes for emphysema because of their role in tissue remodeling. There has been Table 1 . Baseline characteristics of the study group divided into fast and non-decliners
Values are means ± standard error. a Number of packs of cigarettes smoked per day × number of years of smoking. b Change in lung function over a 5 year period measured as % predicted FEV 1 . Percent predicted values are adjusted for height, age and sex. c Lung function at the start of the study. d Percent change in FEV 1 from baseline in response to a bronchodilator. e This is a measure of the responsiveness of the airways to a bronchoconstricting agent (methacholine) expressed as percent decline in FEV 1 per final cumulative dose of methacholine administered (39) . Methacholine response is strongly associated with rate of decline in lung function (40, 41 considerable interest in MMPs and a large number of studies have shown an involvement of MMPs in inflammatory airway disease (11, (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Overexpression of human MMP1 resulted in emphysema in transgenic mice (8) , and deletion of MMP12 in knockout mice prevented smoking-related lung injury (9) . While the relevance of these animal models to human disease has not been proven, they suggest a critical role of these proteinases in lung tissue destruction. Most of the investigated polymorphisms have previously been shown to alter gene expression (6, (15) (16) (17) 29) . The insertion of a G at position -1607 in the promoter of the MMP1 gene creates a binding site for the transcription factor, ETS-1 (15) . Expression studies of reporter gene constructs (15) and ovarian tumor tissue samples (6) demonstrated that the -1607GG allele was associated with higher levels of gene expression.
The T allele of the MMP9 C-1562T polymorphism was associated with higher levels of gene expression in a reporter gene assay and this may be because the T allele has a lower binding affinity for a repressor of transcription (16) . Reporter gene assays were also used to demonstrate that gene expression was negatively correlated to the length of a CA repeat in the MMP9 promoter (29) . CA repeat sequences have been shown to bind nuclear proteins and therefore the length of a CA repeat may have implications for transcriptional regulation (30) .
The A allele of the MMP12 A-82G polymorphism shows a higher affinity for the transcription factor activator protein-1 (AP-1) and higher gene expression in reporter gene assays (17) . The effect of the Asn357Ser polymorphism in MMP12 on the function of the protein is not known. However, this is a non-conservative amino acid substitution that replaces an amino acid with an acidic side chain (Asn) with one that has a hydroxylic side chain (Ser) and therefore may have consequences on the catalytic activity of the protein. The Asn residue at this position is conserved in the mouse and rat, but not the rabbit orthologs of this gene. In other MMPs, both in humans and in other species, this position is invariant but it is glycine rather than asparagine (http://www.ncbi.nlm.nih.gov/). Overall, these data do not provide strong support for a function-changing role for this polymorphism.
The MMP1 (G-1607GG) variant has been associated with ovarian cancer (6), endometrial carcinoma (7) and severity of melanoma (31) . MMP9 polymorphisms have been linked to coronary artery disease (16) and intracranial aneurysms (32) . There was a weak association of an MMP12 polymorphism with coronary artery diameters in diabetic patients (17) . A small study done in Eastern Europe failed to show a significant association with MMP9 (C-1582T) and asthma (33) .
Paradoxically, the frequency of the MMP1 -1607G allele was increased in the fast decliners (0.51) compared with the non-decliners (0.44) ( Table 2 ). The -1607G allele is associated with decreased MMP1 gene expression and therefore would be expected to be protective against a rapid decline in lung function. A possible explanation for this result is that the association is not due to the -1607G allele but is due to an allele in a nearby gene in LD with it.
The association of the MMP1 G-1607GG/MMP12 Asn357Ser haplotypes with rate of decline of lung function is not simply a consequence of the association of MMP1 -1607G with rapid decline, since there is no LD between the two polymorphisms.
Comparison of the haplotypes that were significantly increased or decreased in the fast decliners confirms that it is the combination of alleles rather than a single locus that is responsible for the association. MMP1 -1607G in combination with MMP12 Asn357 was significantly increased in the fast decliners, whereas MMP1 -1607G with MMP12 Ser357 was significantly decreased in the fast decliners. This suggests that MMP1 -1607G, by itself, is not the causal allele for this association. MMP12 Asn357Ser genotype was not associated with rate of decline of lung function (Table 3) suggesting that, by itself, this polymorphism is not causal. However, the haplotypes were associated with rate of decline of lung function suggesting an interaction between the alleles. Alternatively, the haplotypes may be a marker for, and in LD with, the true causative allele that is in the immediate chromosomal vicinity. Other metalloproteinase genes are located in the 11q22-q23 region and are found in the following order; MMP7-MMP20-MMP8-MMP10-MMP1-MMP3-MMP12-MMP13 (GenBank accession no. NT_009151). However, apart from MMP1 and MMP12, none of these metalloproteinases has been implicated in the pathogenesis of COPD.
The lack of association in this study strongly suggests that the investigated MMP9 polymorphisms do not contribute to the pathogenesis of smoking-related decline in lung function. We had excellent power to detect an association of these polymorphisms with the rate of decline of lung function in the two groups of smokers. We could detect an OR of 1.7 or greater for MMP9 CA repeat and MMP9 C-1562T with a power of >80% given the size of our study. Therefore, we were able to conclude that the studied polymorphisms are unlikely to have even a minor influence on rate of decline of lung function.
In summary, this is the first study to address the influence of the majority of known function-altering polymorphisms within the MMP1, MMP9 and MMP12 genes on rate of decline of lung function in smokers. Our data suggest that polymorphisms in the MMP1 and MMP12 genes, but not MMP9, are either causative factors in smoking-related lung injury or are in LD with such factors. 
MATERIALS AND METHODS

Subjects
Subjects were selected from the participants in the National Heart, Lung and Blood Institute, Lung Health Study. The design of this multi-center, randomized clinical trial is described more extensively elsewhere (34) . Study participants were healthy current smokers, 35-60 years of age, who had mild to moderate airflow obstruction based on forced expiratory volume in 1 s (FEV 1 ) and forced vital capacity (FVC) lung function measurements (FEV 1 = 55-90% of predicted and FEV 1 /FVC ≤ 0.70). Exclusion criteria included serious illnesses such as cancer, heart attack or stroke or other important conditions that required medical treatment. The primary outcome was rate of decline of FEV 1 over a follow-up period of 5 years. The two extremes of the distribution of rate of decline were utilized in this study: individuals with a rapid decline of lung function (decline in FEV 1 > 3.0% of predicted value per year) and individuals with an absence of decline over the same period (increase in FEV 1 > 0.4% of predicted value per year).
Of the 3216 persistent smokers in this cohort, 303 were chosen for their rapid decline of lung function and 324 were selected because of absence of decline. Of this group, 595 were Caucasians and 32 were of other ethnic groups. Due to the potential for false positive associations in ethnically stratified populations we studied the Caucasian participants separately. There were insufficient individuals in the other ethnic groups to provide statistically meaningful comparisons. Genotypic data for any of the polymorphisms were unavailable in four of the Caucasian participants.
Genotyping
DNA was extracted from blood samples using a standard phenol/chloroform protocol (35) . The DNA sequence flanking the polymorphic region of each gene was amplified by PCR. Negative controls without DNA template were included with each set of reactions. All analyses were performed blinded with respect to subject characteristics. Genotypes were confirmed by a second person not directly involved in the study, and by dideoxynucleotide sequencing for a representative number of samples of each genotype.
MMP12 (Asn357Ser), MMP12 (A-82G), MMP9 (C-1562T).
The primers used to amplify the DNA sequences containing the MMP12 (Asn357Ser), MMP12 (A-82G) and MMP9 (C-1562T) single nucleotide polymorphisms are summarized in Table 5 .
Restriction enzyme digestion was used to analyze for presence of the mutation within the PCR products (Table 5) . Digested PCR products were loaded on a 3% (MMP12) or 2% (MMP9) agarose gel containing ethidium bromide and visualized in UV light (Fig. 1) .
MMP1 (G-1607GG).
The following primers flanking the MMP1 (G-1607GG) insertion/deletion polymorphism were used to amplify the sequence by PCR: 5′-TGC CAC TTA GAT GAC CAA ATT G-3′ (sense) and 5′-GAT TCC TGT TTT CTT TCT GCG T-3′ (antisense). PCR conditions were as follows: 30 cycles of 94°C for 30 s, 60°C for 30 s and 72°C for 20 s. The presence of the insertion/deletion alleles was assayed by heteroduplex analysis. Figure 2 shows the sequence of the induced heteroduplex generator. After amplification, 4 µl of 6× sucrose loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 40% sucrose in water), 10 µl of PCR product Table 5 . PCR conditions for MMP9 and MMP12 restriction fragment length polymorphism assays
The underlined bases are mismatches designed to introduce a restriction site into the PCR product. and 10 µl of the amplified heteroduplex generator were denatured at 94°C for 10 min. The samples were allowed to cool slowly on the PCR machine heating block for 30 min to allow renaturation and formation of the heteroduplexes. Electrophoresis was performed on a 15% polyacrylamide gel. Bands were visualized by a UV transilluminator after staining of the gel with ethidium bromide.
MMP9 (CA-repeat).
To determine the numbers of the (CA) n repeats in the MMP9 promoter region, PCR products were generated using a fluorescently labeled (6-FAM) forward primer (5′-GTG GAG AGA GGA GGA GGT GGT GTA AGC-3′) and an unlabeled reverse primer (5′-TGG TGA GGG CAG AGG TGT CTG ACT GC-3′), which were designed according to the published sequence (GenBank accession no. M68343) (36) . The PCR was performed over 30 cycles of 94°C for 20 s, 59°C for 40 s and 72°C for 20 s. Following PCR amplification, products were mixed with an internal standard (Rox-350, Applied Biosystems, Mississauga, ON). Alleles were separated by a laser-based automated DNA sequencer (ABI PRISM 3700). The sizes of the fluorescently labeled PCR products were calculated from a standard curve made using the internal standards. DNA standards containing 14, 17, 21 and 23 CA repeats were identified by direct sequencing and were included in each experiment as positive controls.
Statistical analysis
The results are presented as genotype and allele frequencies for both fast and non-decliners among the Lung Health Study participants. χ 2 tests for statistical significance were performed on allele and genotype frequencies with the exception of the MMP9 CA repeat allele frequencies. Due to the large number of rare alleles, we performed a Monte Carlo test (37) . In this test, 10 000 random simulations were performed to generate tables having the same marginal totals as the observed data, and the number occurrences of a χ 2 value greater than or equal to the χ 2 value associated with the real table was counted. The associations were also analyzed by binary logistic regression to adjust for potential confounding factors. Factors included in the analyses were smoking history, age, sex and initial level of lung function (pre-bronchodilator predicted FEV 1 percentage). Unpaired t-tests were used to compare baseline values. All tests were performed using the JMP Statistics software package (SAS Institute Inc.) Haplotype frequencies were estimated using the expectationmaximization (EM) algorithm (37) , since haplotypes cannot be discerned directly from double heterozygotes. The EM algorithm begins by setting the haplotype frequencies in the double heterozygotes to the values that would be observed under linkage equilibrium. The values are then regarded as real data and used to calculate haplotype frequencies in the entire population. These revised haplotype frequencies are used to obtain revised expected values in the double heterozygotes. This cycle is repeated until the changes in haplotype frequencies from one iteration to the next become negligible and this yields maximum likelihood estimates of the haplotype frequencies. The Arlequin software package was used to perform these estimations, to test for LD and for Hardy-Weinberg equilibrium (38) . LD was calculated in order to help interpret the haplotype data. For example, an association of a haplotype, composed of two alleles not in LD, with rate of decline of lung function suggests an interaction between the alleles. In the presence of LD, only one allele in a haplotype may be causal and the other alleles simply in LD with the causal allele. The four different generated heteroduplexes can be clearly separated as four bands: two upper bands (∼250 and 300 bp, GG allele), two lower bands (∼200 bp, G allele). The homoduplexes appear as one band at ∼130 bp. SM, 100 bp size marker.
